Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment
Alzheimer's & Dementia · 2025-02 · 21 (2)
DOI: 10.1002/alz.14412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 28.12.2024. Verfasst von Greet Vanderlinden und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Cognitive Dysfunction, tau Proteins, Synapses, Amnesia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FWO, KU Leuven internal C2 funding, Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
INTRODUCTION The longitudinal progression of synaptic loss in Alzheimer's disease (AD) and how it is affected by tau pathology remains poorly understood. METHODS Thirty patients with amnestic mild cognitive impairment (aMCI) and 26 healthy controls underwent cognitive evaluations and tau, synaptic vesicle protein 2A (SV2A), and amyloid positron emission tomography. Twenty‐one aMCI underwent 2‐year follow‐up (FU) investigations. RESULTS Tau levels in aMCI increased longitudinally in Braak regions III through VI but not in Braak regions I and II. SV2A decreased longitudinally in all Braak regions in aMCI. Baseline tau was negatively associated with longitudinal SV2A loss in early Braak regions and with SV2A at FU across regions. Baseline tau and longitudinal change in SV2A were associated with longitudinal cognitive decline. DISCUSSION Tau accumulation reaches a plateau in early Braak regions already in the aMCI stage of AD. In early Braak regions, the association between baseline tau and longitudinal SV2A loss might reflect synaptic dysfunction caused by tau pathology. Highlights Tau accumulation reached a plateau in early Braak regions in amnestic mild cognitive impairment (aMCI) patients. aMCI patients show widespread longitudinal decrease in synaptic vesicle protein 2A (SV2A) over 2 years. Baseline tau was predictive for longitudinal SV2A loss. The tau–SV2A relation showed individual variability and was negative across patients. Baseline tau and longitudinal SV2A change were associated with change in cognition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven, Belgium.
- Leuven Brain Institute, KU Leuven, Leuven, Belgium.
- Department of Neurology, University Hospitals UZ Leuven, Leuven, Belgium.
- VIB, Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium.
- Department of Neurosciences, KU Leuven, Leuven, Belgium.
- Department of Geriatric Psychiatry, University Hospitals UZ Leuven, Leuven, Belgium.
ORCID-Profile: Greet Vanderlinden
Förderung
- FWO
- KU Leuven internal C2 funding
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Vanderlinden, G., Koole, M., Michiels, L., Lemmens, R., Vandenbulcke, M., & Van Laere, K. (2025). Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14412
Vancouver
Vanderlinden G, Koole M, Michiels L, Lemmens R, Vandenbulcke M, Van Laere K. Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14412
BibTeX
@article{Vanderlinden2025,
author = {Vanderlinden, Greet and Koole, Michel and Michiels, Laura and Lemmens, Robin and Vandenbulcke, Mathieu and Van Laere, Koen},
title = {Longitudinal synaptic loss versus tau Braak staging in amnestic mild cognitive impairment},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {2},
doi = {10.1002/alz.14412}
}
EUVIMED